Mr Samuel T Anaya, PT DPT OCS MTC | |
6970 N Oracle Rd Ste 130, Tucson, AZ 85704-4237 | |
(520) 219-5825 | |
(520) 219-5827 |
Full Name | Mr Samuel T Anaya |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 6970 N Oracle Rd Ste 130, Tucson, Arizona |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255511036 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 2414 (Arizona) | Secondary |
225100000X | Physical Therapist | LPT-002414 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Samuel T Anaya, PT DPT OCS MTC 600 Oakmont Ln Ste 600c, Westmont, IL 60559-5548 Ph: (630) 575-1980 | Mr Samuel T Anaya, PT DPT OCS MTC 6970 N Oracle Rd Ste 130, Tucson, AZ 85704-4237 Ph: (520) 219-5825 |
News Archive
A new study by researchers at the University of Oxford and the Trip Medical Database and published on the preprint server medRxiv* in August 2020 as part of the ongoing Open Evidence Review on Transmission Dynamics of COVID-19 reports the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in feces and the need for precautions to prevent orofecal spread in the surroundings of confirmed or suspected cases.
Published in the August issue of Fertility and Sterility, the study reviewed seven years of U.S. statistics from all the fertility clinics that report data on reproductive techniques.
According to the latest research in the U.S., a genetic variation may protect against alcoholism, and this could lead to a novel preventative treatment. The researchers say that a gene variant known as CYP2EI is linked to people's response to alcohol.
Pharmasset, Inc. today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not been treated previously.
› Verified 8 days ago